Incellipan (Sorbitan Trioleate, Polysorbate 80, Sodium Citrate, Squalene, Citric Acid, Influenza Virus A/Turkey/)

The vaccine contains inactivated viral antigens together with adjuvants such as squalene. After intramuscular injection, antigen‑presenting cells process the antigens, prompting the immune system to generate specific antibodies and T‑cell responses. This prepares the body to recognise and neutralise the live influenza virus if encountered.

The dosage and schedule for Incellipan are determined by the prescribing healthcare professional based on age, health status, and local immunisation guidelines. The prescriber will decide the appropriate volume and timing for each individual patient.

Safety data for Incellipan in pregnant or lactating individuals are limited. Healthcare providers should evaluate the potential benefits against any theoretical risks and discuss the decision with the patient. In many regions, inactivated influenza vaccines are considered acceptable when indicated.

To place an order, submit an enquiry on the Incellipan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and the necessary import documentation.

Incellipan uses a squalene‑based adjuvant, which can enhance the immune response and may allow for dose‑sparing compared with some non‑adjuvanted vaccines. Its efficacy and safety profile are comparable to other licensed inactivated influenza vaccines, while offering the added benefit of potentially broader protection against A/Turkey strains.

Incellipan must be stored refrigerated at 2 °C to 8 °C. It should be kept in the original packaging, protected from light, and must not be frozen or shaken vigorously. Maintaining the cold chain during transport and storage is essential to preserve vaccine potency.

The vaccine is given as a single intramuscular injection, typically into the deltoid muscle of the upper arm. The administration is performed by a qualified healthcare professional using aseptic technique. The injection site should be observed for any immediate reactions.

Serious adverse events, although rare, include anaphylaxis, Guillain‑Barré syndrome, high‑grade fever lasting more than 48 hours, seizures (particularly in children), and myocarditis or pericarditis. Patients should be monitored after vaccination and instructed to seek medical attention if severe symptoms develop.

Individuals with a known severe allergy to any component of the vaccine, such as squalene, polysorbate 80, or the influenza virus antigens, should not receive Incellipan. Those who have experienced a severe reaction to a previous dose of an influenza vaccine should also avoid it. Consultation with a healthcare provider is essential for any contraindications.